Cargando…
Integrated treatment of hepatitis C virus infection among people who inject drugs: A multicenter randomized controlled trial (INTRO-HCV)
BACKGROUND: The standard pathways of testing and treatment for hepatitis C virus (HCV) infection in tertiary healthcare are not easily accessed by people who inject drugs (PWID). The aim of this study was to evaluate the efficacy of integrated treatment of chronic HCV infection among PWID. METHODS A...
Autores principales: | Fadnes, Lars T., Aas, Christer Frode, Vold, Jørn Henrik, Leiva, Rafael Alexander, Ohldieck, Christian, Chalabianloo, Fatemeh, Skurtveit, Svetlana, Lygren, Ole Jørgen, Dalgård, Olav, Vickerman, Peter, Midgard, Håvard, Løberg, Else-Marie, Johansson, Kjell Arne |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8205181/ https://www.ncbi.nlm.nih.gov/pubmed/34061883 http://dx.doi.org/10.1371/journal.pmed.1003653 |
Ejemplares similares
-
Integrated treatment of hepatitis C virus infection among people who inject drugs: study protocol for a randomised controlled trial (INTRO-HCV)
por: Fadnes, Lars T., et al.
Publicado: (2019) -
Integrated care of severe infectious diseases to people with substance use disorders; a systematic review
por: Vold, Jørn Henrik, et al.
Publicado: (2019) -
Subjective symptoms and serum methadone concentrations: what should guide dose adjustments in methadone maintenance treatment? A naturalistic cohort study from Norway
por: Chalabianloo, Fatemeh, et al.
Publicado: (2021) -
Impact of clinical and sociodemographic factors on fatigue among patients with substance use disorder: a cohort study from Norway for the period 2016–2020
por: Vold, Jørn Henrik, et al.
Publicado: (2020) -
On the path towards universal coverage of hepatitis C treatment among people receiving opioid agonist therapy (OAT) in Norway: a prospective cohort study from 2013 to 2017
por: Aas, Christer Frode, et al.
Publicado: (2020)